Imodium (Loperamide Hydrochloride)

Loperamide acts as a peripheral μ‑opioid receptor agonist in the gut. By binding to these receptors, it decreases the release of excitatory neurotransmitters, reduces smooth‑muscle contractions, prolongs transit time, and enhances absorption of water and electrolytes, resulting in firmer stools.

The appropriate dose of Imodium is determined by a prescriber based on the individual’s age, severity of symptoms, and clinical condition. Patients should follow the healthcare professional’s instructions and the product labeling for dosing guidance.

Safety data for loperamide in pregnancy are limited, so it should only be used if the potential benefit justifies the risk and after consulting a healthcare provider. During breastfeeding, loperamide may be excreted in milk; use only under medical advice.

To order Imodium, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imodium (loperamide) is a peripheral μ‑opioid receptor agonist, offering targeted reduction of gut motility without significant central opioid effects at recommended doses. Compared with adsorbents like bismuth subsalicylate, loperamide provides faster symptom control but requires caution in patients with constipation or obstructive bowel conditions.

Imodium tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Imodium is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed. It can be taken with or without food, but patients should follow the dosing instructions provided by their healthcare professional.

Serious risks include severe constipation, paralytic ileus, toxic megacolon, and rare cardiac arrhythmias, especially when combined with CYP3A4 or P‑gp inhibitors. Any signs of abdominal pain, bloating, or inability to pass stool should prompt immediate medical evaluation.

Imodium should be avoided in individuals with known hypersensitivity to loperamide, those with acute dysentery, bacterial enterocolitis, or colitis caused by C. difficile. Patients with severe constipation, intestinal obstruction, or a history of paralytic ileus should also refrain from using it unless directed by a physician.